Buserelin is a LHRH agonist used for the palliative treatment of hormone-dependent advanced carcinoma of the prostate gland in males and treatment of endometriosis in females. Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR).
- Mechanism
- Curator reviewed
Buserelin stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). Buserelin desensitizes the GnRH receptor, reducing the amount of gonadotropin. In males, this results in a reduction in the synthesis and release of testosterone. In females, estrogen secretion is inhibited. While initially, there is a rise in FSH and LH levels, chronic administration of Buserelin results in a sustained suppression of these hormones.
- Primary indication
- Buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.Curator reviewed · 2 structured indications
- First approval
- Canada, 2020
- Also known as
- Etilamide · Tiloryth
- Code names
- HOE-766 · ICI-123215 · S74-6766
- Brand names
Resolves to
What you can answer from here — as of September 23, 2026
Which drugs share a target with Buserelin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account